Purple Biotech Highlights Significant Advantages of the Novel CAPTN-3 Tri-Specific Antibody Platform at the EACR 2025 Annual Congress

Core Insights - Purple Biotech Ltd. presented new preclinical data on its CAPTN-3 tri-specific antibody platform at the EACR 2025, showcasing its potential to overcome tumor immune evasion and drug resistance [1][2] Group 1: CAPTN-3 Platform Overview - The CAPTN-3 platform enables the creation of tri-specific antibodies that activate both innate and adaptive immune systems, enhancing anti-tumor responses [2][6] - The lead product, IM1240, targets the 5T4 antigen and has shown robust in vivo anti-tumor activity, particularly in triple negative breast cancer models [7][10] - The design includes an anti-NKG2A arm that synergizes with the anti-CD3 arm, demonstrating significant cytotoxic effects against solid tumor cells [3][4][5] Group 2: Mechanism of Action - The CAPTN-3 platform features a conditional activation mechanism, where the CD3 arm is activated only in the tumor microenvironment, minimizing systemic effects [6][7] - The anti-NKG2A arm plays a crucial role in reinvigorating exhausted T cells, enhancing their ability to kill tumor cells [4][5] - The platform's design allows for a modular approach, enabling the development of various tribodies with different target combinations [7][10] Group 3: Clinical Implications - Preclinical data indicate that the CAPTN-3 platform can lead to sustained tumor regression in animal models, highlighting its therapeutic potential [5][7] - The platform's ability to engage both T cells and NK cells suggests a promising avenue for developing effective cancer therapies [6][10] - The company is advancing multiple candidates within its oncology pipeline, including CM24 and NT219, alongside CAPTN-3 [10]